Rituximab in indolent lymphoma: The single-agent pivotal trial

Seminars in Oncology

Volumn 26, Issue 5 SUPPL. 14, 1999, Pages 79-87

  McLaughlin, P ^a   Hagemeister, F B ^a   Grillo Lopez, A J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; RITUXIMAB;

ADULT; ADVERSE DRUG REACTION; ARTICLE; B CELL LYMPHOMA; CLINICAL TRIAL; DRUG BLOOD LEVEL; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; REMISSION; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; SURVIVAL ANALYSIS;

EID: 0032719758     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)